Synopsis: German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised…
Category:
Boehringer Ingelheim
-
-
Boehringer IngelheimCompaniesGlobal MarketPharma Science & Research
Boehringer Ingelheim, Evotec and BioMérieux Launch Aurobac, a joint venture to fight Antimicrobial Resistance
by adminby adminSummary : Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;…
-
Boehringer Ingelheim
Boehringer Ingelheim and OSE Immunotherapeutics To Present Biomarker Analyses from the Phase 1 Clinical Trial with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors
by adminby adminSummary : OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE), today announced that early biomarker analyses from the ongoing Phase 1 clinical trial with SIRPα…
-
Boehringer IngelheimGlobal Market
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
by adminby adminSummary : The leading research-driven biopharmaceutical company Boehringer Ingelheim and precision medicine software company Lifebit Biotech, Ltd. (Lifebit) today announce partnership in…